Supraventricular Tachycardia (SVT)

Supraventricular Tachycardia (SVT)

News & Stories

News Release

U-M launches national search for next executive vice president for medical affairs and CEO of Michigan Medicine

President Domenico Grasso and President-elect C. Cybele Raver are working together to launch the search for the university’s next executive vice president for medical affairs and CEO of Michigan Medicine.
Photo of woman with shoulder-length, blond streaked hair, wearing a V-neck black blouse.
Department News

MDisability Manager Dawn Michael helps drive the program to achieve its mission

Dawn Michael, MDisability program manager, discusses what drives her passion for advancing health equity for people with disabilities.
Rajesh Mangrulkar, MD, FNAP
Department News

From the Executive Director’s Desk: November 2026

Strong education innovations need strong partnerships to stand the test of time. Sustaining these interventions requires ongoing collaboration and institutional support. It also means bringing together the expertise and resources needed to help promising work continue beyond its initial development and become part of ongoing practice.
Picture of woman in the clinic room, interacting with two people in white doctor's coats and a male ASL interpreter.
Department News

Deaf Health Clinic is first of its kind in Michigan to care for deaf and hard of hearing patients

The Deaf Health Clinic at Michigan Medicine's Dexter Medical Center cares for those who are deaf and hard of hearing. It is the first of its kind clinic in Michigan.
Feldman Lab Image
Research News

CPOD Faculty Publication Spotlight - Feldman Lab

In the September 2026 issue of The FASEB Journal, the Feldman Lab published "NONcNZO10/LtJ and TALLY-HO/JngJ Mice as Novel Models of Diabetic Peripheral Neuropathy."
Matthias Kretzler
Department News

Semaglutide and Kidney Protection in Type 2 Diabetes

Published in Nature Medicine (October 2026), this randomized, placebo-controlled clinical trial investigated the kidney-protective mechanisms of semaglutide in individuals with type 2 diabetes and chronic kidney disease. The 52-week study involved 106 participants and integrated advanced kidney imaging, tissue biopsy, and molecular profiling to examine treatment-related changes in kidney health.